A 12-Week Double-Blind, Parallel-Group, Placebo- and Active- Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 Mcg/0.5 mL Delivered by OMRON MicroAir NE-U22V Nebulizer in the Treatment of Patients With Chronic Obstructive Pulmonary Disease

Trial Profile

A 12-Week Double-Blind, Parallel-Group, Placebo- and Active- Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 Mcg/0.5 mL Delivered by OMRON MicroAir NE-U22V Nebulizer in the Treatment of Patients With Chronic Obstructive Pulmonary Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2010

At a glance

  • Drugs Formoterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mylan Specialty
  • Most Recent Events

    • 09 Nov 2010 Actual end date (May 2007) added as reported by ClinicalTrials.gov.
    • 09 Nov 2010 Actual initiation date (January 2006) added as reported by ClinicalTrials.gov.
    • 24 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top